The Evaluation of Hypoxia Imaging in Patients With Pancreatic Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
This is a diagnostic study to look for low levels of oxygen (hypoxia) in pancreatic cancer
using an imaging test called positron emission tomography (PET). Hypoxia can influence how
pancreatic cancer grows and responds to treatments such as chemotherapy and radiation therapy.
The use of PET scans to measure hypoxia may be better and simpler than the approaches used
previously. This study will assess whether or not PET scans using a tracer called 18F-FAZA
(18F-Fluoroazomycin Arabinoside) can provide useful information about hypoxia in pancreatic
cancer. Also as part of the study, a blood sample will be taken to study biomarkers
(substances in the body that may be important indicators of hypoxia and/or pancreatic
cancer) that may be useful in studying pancreatic cancer and hypoxia.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society